valsartan / Generic mfg. - LARVOL DELTA

Encapsulation-based enhancements in modern drug delivery systems. (PubMed, Int J Pharm) - "In addition, the pharmaceutical industry has commercialized many encapsulated drugs, such as anti-inflammatory (ibuprofen, dexamethasone), high blood pressure drugs (valsartan, azilsartan), proton pump inhibitors (lansoprazole), anti-cancer (carboplatin, carmustine, cisplatin, trastuzumab, cytarabine, paclitaxel, doxorubicin (DOX), vincristine) antiparasitic (amphotericin), antifungal (clotrimazole), and hormonal (melatonin (MLT))). It can render drugs more convenient and user-friendly for various therapeutic purposes and help to enhance their performance, functionality, and effectiveness. This comprehensive review examines the encapsulation technologies employed in the pharmaceutical industry, highlighting notable examples of encapsulated drugs that demonstrate their mechanism of action and potential therapeutic effects in vitro, in vivo, and through clinical trials, with relevance to various diseases."

Journal • Review • Cardiovascular • Hypertension • Oncology

Decoding the Neuroprotective Intervention of Angiotensin Receptor Blockers: A Multimodal Approach Using In Silico Network Pharmacology, Molecular Modeling, and In Vivo Validation of Key Markers. (PubMed, ACS Chem Neurosci) - "Building on these findings, this study sought to compare the activity of azilsartan with other commonly used ARBs, including telmisartan, olmesartan, valsartan, eprosartan, irbesartan, and candesartan, using an integrative network pharmacology approach. To experimentally validate these predictions, in vivo studies were conducted in a scopolamine-induced memory-impaired model, which demonstrated significant restoration of the levels of AKT1 and PIK3CA. These findings clearly demonstrate the PI3K/AKT modulating effects of azilsartan, reinforcing its repurposing potential in dementia and related disorders, thereby expanding novel therapeutic opportunities within this drug class."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • AKT1 • PIK3CA • PIK3CB

Two isotypical disodium salts of the antihypertensive agent valsartan. (PubMed, Acta Crystallogr C Struct Chem) - "The surface of these layers is hydrophobic due to the coating of alkyl and aryl groups. Numerous O-H...O and O-H...N hydrogen bonds are observed within the layers."

Journal

Antihypertensive drugs for hyperuricemia in patients with hypertension: a systematic review and network meta-analysis of Chinese trials. (PubMed, BMC Cardiovasc Disord) - "Based on the only available eligible evidence, the combination of losartan and amlodipine was the optimal dual therapy for Chinese patients with hypertension and hyperuricemia, while allisartan and losartan were the most effective monotherapies for lowering serum uric acid. These findings are not generalizable to non-Chinese populations, reflecting a gap in global evidence rather than intentional study scope restriction."

Journal • Retrospective data • Review • Cardiovascular • Hypertension

Multisystem Complications and Therapeutic Trends in Scleroderma Renal Crisis: Insight from a Five-Year Retrospective Cohort Study (KIDNEY WEEK 2025) - "Renal: Acute renal failure in 12.0% ESRD in 2.8%, renal transplant in 0.7%, Hemodilaysis in 2.1%, Cardiovascular: NSTEMI in 2.8%, STEMI in 0.8%, Neurological: Stroke in 2.3%, Pulmonary: Edema in 2.4%, Pulmonary Hypertension in 16.8%, Pulmonary fibrosis in 7.3%, Treatment: Antihypertensives: ACEi (Captopril in 2.4%, enalapril in 1.2%, and ARBs: Losartan in 5.6%, valsartan in 2.4%). Immune suppressants: Hydroxychloroquine (HCQ) in 7.9%, methotrexate (MTX) in 3.7%, mycophenolate in 12.7%, rituximab in 4.1%, prednisone in 18.4%, methylprednisone in 18.3% of the cohort...Low utilization of ACEi and ARBs indicates potential therapeutic gaps. Further research to refine treatment strategies is essential to improve mortality and patient outcomes."

Retrospective data • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Hypertension • Immunology • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

Predicting Pharmacokinetics of Drugs in Patients with Heart Failure and Optimizing Their Dosing Strategies Using a Physiologically Based Pharmacokinetic Model. (PubMed, Pharmaceutics) - "Eight commonly used drugs (digoxin, furosemide, bumetanide, torasemide, captopril, valsartan, felodipine and midazolam) for treating HF and its comorbidities were selected. A PBPK model was successfully developed to predict the plasma concentration-time profiles of the eight tested drugs in both healthy subjects and HF patients. Furthermore, this model may also be applied to guide digoxin dose optimization for HF patients."

Journal • PK/PD data • Cardiovascular • Congestive Heart Failure • Heart Failure

Adherence, Switches, and Drug Spending After Angiotensin Receptor Blocker Recalls and Shortages. (PubMed, JAMA Health Forum) - "From 2018 to 2019, hundreds of valsartan, losartan, and irbesartan products were recalled due to ingredient impurities. This cohort study shows that access to alternatives may have mitigated gaps in treatment during the 2018 to 2019 ARB recalls and drug shortages. Potential disparate impacts among certain subgroups highlight the need for policies to mitigate financial and other systematic access barriers to receiving health care during drug shortages."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hypertension • Nephrology • Renal Disease

Therapeutic potential of valsartan in overcoming chemoresistance in human glioblastoma. (PubMed, Sci Prog) - "This study aimed to evaluate the effects of valsartan, a renin-angiotensin system inhibitor, on GBM cell lines with and without temozolomide (TMZ) resistance.MethodsTMZ-resistant GBM clones were established by repeatedly exposing LN229 and GBM8401 human glioma cells to high doses of TMZ, followed by selective culture of the surviving populations. RNA sequencing revealed that valsartan regulates the cell cycle and induces G1-phase arrest, as evidenced by cell cycle flow cytometry. Moreover, APLN, an angiogenesis-related gene, was identified as a potential downstream target whose expression is significantly inhibited by valsartan.ConclusionsThis study revealed that valsartan is a novel strategy for treating gliomas with drug resistance."

Journal • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

Modeling the fate of organic micropollutants in agricultural soils: Laboratory parameterization and field-scale implications. (PubMed, J Contam Hydrol) - "Four OMP (adamantan-1-amine, carbamazepine, diclofenac, and sulfamethoxazole) exhibited biphasic sorption behavior, which was best described by a two-site kinetic model. Three OMP (acesulfame, saccharin, and valsartanate) showed negligible sorption but, following lag phases between 4 and 9 days, indicated microbial adaptation...The remaining compounds (diatrizoate, trifluoromethanesulfonate, primidone) showed neither sorption nor degradation...The results suggest that simplified equilibrium and immediate-degradation assumptions may be sufficient for risk assessment regarding to OMP in homogeneous soils with predominantly uniform flow conditions. Overall, this study presents a comprehensive framework for bridging laboratory observations with field-scale modeling, offering new insights into OMP fate and guiding efficient parameterization strategies for environmental risk assessment for the management of reclaimed water."

Journal

Effects of antihypertensives on the degradation behavior of AZ31 alloy in in-vitro environment. (PubMed, Sci Rep) - "Effects of seven antihypertensives of Losartan Kalicum(LK), Atenolol(ATEN), Nifedipine(NF), Hydrochlorothiazide(HCTZ), Valsartan(VLA), Furosemide(FUR) and Captopril(CAP) have been investigated on the degradation behavior of AZ31 alloy in simulated body fluid (Hank's solution). The surface analysis reveals that the addition of LK, NF and HCTZ can reduce degradation rate by promoting the growth of hydroxyapatite, increasing the protection effect of corrosion film formed. The present results may enhance the corrosion resistance of Mg-based orthopedic implants."

Journal • Preclinical • Orthopedics

In vitro two stage one compartment dumping test data and absorption/formulation PBBM modeling to explain a bioequivalence failure of valsartan formulations. (PubMed, Eur J Pharm Biopharm) - "The study demonstrated that a simple dynamic dissolution methodology can effectively predict in vivo bioequivalence and formulation performance. The application of the "dumping test" provided valuable insights into the dissolution characteristics of different formulations, highlighting its potential as a cost-effective and practical tool for biopredictive studies."

Journal • Preclinical

Carvacrol alleviates diabetic cardiomyopathy in rats: Targeting Cuproptosis pathway. (PubMed, Toxicol Appl Pharmacol) - "Rats were divided into: normal control, CAR control, diabetic group, and diabetic rats treated with CAR (20 mg/kg) or valsartan (30 mg/kg) for six weeks...Treatment with CAR ameliorated all deviations mentioned above. These findings highlight the cardioprotective effects of CAR against DCM through the normalization of cardiac copper homeostasis and inhibition of cuproptosis."

Journal • Preclinical • Cardiomyopathy • Cardiovascular • Diabetes • Fibrosis • Immunology • Metabolic Disorders • ATP7A • ATP7B • LIAS • TNNI3

Drug-associated hypertensive crisis: a disproportionality analysis of the FAERS database. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Ramipril (282 cases) and valsartan (192 cases) ranked as the second and third medications, respectively. The top 5 drugs associated with the risk of hypertensive crisis under the ROR algorithm were amlodipine perindopril (ROR = 136.64), methyl aminolevulinate (ROR = 122.78), tranylcypromine (ROR = 105.15), rifapentine (ROR = 39.46), and amiloride hydrochlorothiazide (ROR = 39.36)...Our study showed that numerous medications carry potential risks for drug-associated hypertensive crisis. Further investigation is required to establish causality and inform clinical decision-making."

Journal

Two Cases of IgAN in Healthy Adult Male Bodybuilders Using Testosterone Replacement Therapy (KIDNEY WEEK 2025) - "Case Description Patient A is a 45-year-old gentleman with a medical history of hypertension on valsartan and hypogonadism secondary to anabolic steroid use treated with topical testosterone for the last ten years evaluated for worsening creatinine and proteinuria...Patient B is a 39-year-old gentleman with a medical history of hypertension on lisinopril and hypogonadism secondary to anabolic steroid use treated with testosterone injections for seven months evaluated for worsening serum creatinine...In these adult men, use of testosterone replacement therapy and anabolic androgenic steroids may have affected liver function impairing the clearance of these abnormal IgA immune complexes and leading to the development of IgA nephropathy. This underscores the importance of screening patients using testosterone replacement therapy for bodybuilding."

Clinical • Cardiovascular • Celiac Disease • Chronic Kidney Disease • Endocrine Disorders • Fibrosis • Glomerulonephritis • Hepatology • Hypertension • IgA Nephropathy • Immunology • Infectious Disease • Inflammation • Liver Failure • Nephrology • Renal Disease

Rethinking Risk Stratification in IgAN: A Case Challenging the MEST-C Paradigm (KIDNEY WEEK 2025) - "Home medications included valsartan and as needed ibuprofen...On the following visit, she reported discontinuing prednisone after taking it for 2 months due to significant edema...A short course of steroids significantly reduced proteinuria, albeit with noticeable side effects leading to treatment discontinuation. Nephrotic-range proteinuria in IgAN, even in the absence of severe histologic inflammation, should raise consideration for immunosuppressive"

Clinical • Cardiovascular • Fibrosis • Glomerulonephritis • Hypertension • IgA Nephropathy • Immunology • Inflammation • Nephrology • Renal Disease • Women's Health

Rosuvastatin-Induced Acute Tubular Injury Not Associated with Rhabdomyolysis (KIDNEY WEEK 2025) - "In addition to valsartan, he was taking benzonatate, rosuvastatin, amlodipine, fish oil, vitamin C and albuterol. The pathogenesis for the mechanism of injury is not fully understood but there is some evidence for decreased receptor-mediated endocytosis in proximal renal tubules by statins. Practitioners must be cognizant of this potential complication of rosuvastatin use."

Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Fibrosis • Hypertension • Immunology • Nephrology • Renal Disease

Not All That Glitters Is Diabetes: When Diabetes Glomerulopathy Was Not the Only Answer, a Case Series (KIDNEY WEEK 2025) - "Medications Valsartan, empagliflozin, Sitagliptin/Metformin, Nifedipine...Medications: Valsartan + HCT, NPH insulin, Oxcarbazepine, Hb 7.6, creatinine 5.8, A1c 9.1...Discussion These three different patients with poorly controlled diabetes showed that in some cases it is crucial to perform kidney biopsy since other pathologies could be contributing or causing kidney damage. Although diabetic nephropathy remains the leading cause of end-stage renal disease, it is often assumed without confirmation, which can lead to missed or delayed diagnoses."

Clinical • Amyloidosis • Anemia • Back Pain • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Lupus Nephritis • Lymphoma • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Non-Hodgkin’s Lymphoma • Renal Disease

The Great Masquerader: Phospholipase A2 Receptor-Negative Membranous Nephropathy Secondary to Sarcoidosis (KIDNEY WEEK 2025) - "In the absence of high-risk features for disease progression, the patient received optimal supportive care with diuretics, valsartan, dapagliflozin and therapeutic apixaban. The antigen profile in sarcoidosis-associated MN mimics that of primary MN with PLA2R and neural epidermal growth factor-like 1 being the most common. The causative antigen in our patient remains unknown, although we will send any future kidney biopsy tissue for mass spectrometry to characterise the culprit antigen."

Crohn's disease • Dyslipidemia • Fibrosis • Gastroenterology • Glomerulonephritis • Immunology • Inflammatory Bowel Disease • Lupus Nephritis • Musculoskeletal Pain • Myositis • Nephrology • Renal Disease • Sarcoidosis

A Rare Case of Metformin-Associated Lactic Acidosis with Concurrent Euglycemic Ketoacidosis in a Patient with Type 2 Diabetes (KIDNEY WEEK 2025) - "Case Description A 59-year-old African American female with type 2 diabetes (on metformin 1 g twice daily and a GLP-1 RA), hypertension (on valsartan), and stage 3A chronic kidney disease (CKD) (baseline creatinine 1.2 mg/dL) presented with three days of vomiting, abdominal pain, and acute vision loss after caring for sick grandchildren. MALA occurs when metformin accumulates, as in AKI, and inhibits mitochondrial complex I, shifting pyruvate metabolism toward lactate production. Prompt and intensive RRT; beginning with high-flux hemodialysis and followed by high-dose CVVHDF with bicarbonate pre blood pump is effective in correcting acidemia and eliminating metformin."

Clinical • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Targeting FoxO1-STX17-Mediated Autophagic Flux: Quercetin's Therapeutic Mechanism in Diabetic Nephropathy. (PubMed, Eur J Pharmacol) - "Quercetin alleviates DN by targeting FoxO1 to restore STX17-dependent autophagosome-lysosome fusion, thereby resolving autophagic stress. These findings support quercetin as a promising therapeutic candidate for DN."

Journal • Diabetic Nephropathy • Nephrology • Renal Disease

Severe non-cardiogenic pulmonary edema following low-dose amlodipine ingestion: a case report. (PubMed, Ann Med Surg (Lond)) - "A 40-year-old male with newly diagnosed hypertension, treated with amlodipine 5 mg and valsartan 160 mg daily for 4 days, was presented with severe sudden dyspnea, palpitations, and restlessness...Amlodipine was discontinued, and hydrochlorothiazide 12.5 mg daily was initiated, leading to rapid improvement...This case highlights a potential rare association between low-dose amlodipine and severe NCPE, warranting further investigation. Clinicians should consider amlodipine in unexplained NCPE cases, with early discontinuation to improve outcomes."

Journal • Acute Respiratory Distress Syndrome • Cardiovascular • Hypertension • Pulmonary Disease • Respiratory Diseases

Efficacy and safety of Ambrisentan on idiopathic membranous nephropathy----a prospective, multi-center, randomized and controlled study (ChiCTR) - P=N/A | N=80 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Army Medical University; Army Medical University

New trial • Glomerulonephritis • Renal Disease

A RARE CASE OF CARDIOGENIC SHOCK SECONDARY TO METHAMPHETAMINE USE COMPLICATED BY ADRENAL INSUFFICIENCY (CHEST 2025) - "He was hypotensive, requiring Norepinephrine and Dobutamine for blood pressure and ionotropic support...He was started IV Hydrocortisone...He underwent pulmonary artery catheter guided diuresis and afterload reduction with sodium nitroprusside. He was weaned off vasopressor support, extubated and was initiated on Metoprolol Succinate, Valsartan and Dapagliflozin and discharged with a LifeVest... Cardiogenic shock due to dilated cardiomyopathy can be a result of methamphetamine use. Adrenal insufficiency can be a later sequalae. According to a meta-analysis in 2021, there is a moderate prevalence of adrenal insufficiency in cardiogenic shock, however further studies are needed to quantify the correlation.(2)It is important to identify risk factors for the development of cardiogenic shock in otherwise healthy patients, such as methamphetamine use."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Cough • Endocrine Disorders • Heart Failure • Hypoglycemia • Metabolic Disorders • Myocardial Infarction • Nephrology • Renal Disease • Respiratory Diseases

CHALLENGES IN THE MANAGEMENT OF PHEOCHROMOCYTOMA AND CORONARY ARTERY DISEASE REQUIRING CABG: A CASE REPORT (CHEST 2025) - "Continuous nicardipine IV was started to address the hypertensive emergency, which was weaned off after a dose of doxazosin...Her hypertension improved on a regimen of valsartan, nifedipine, and hydralazine... While both pheochromocytoma and cardiovascular disease are so closely intertwined, there is no standard practice when treating both severe CAD and pheochromocytoma simultaneously. Unfortunately, there is little information regarding survival rates and procedural progression when treating these two conditions simultaneously. Given the high risk nature of these diseases and procedures, further investigation needs to be conducted."

Case report • Clinical • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Heart Failure • Hypertension • Myocardial Infarction • Oncology • Solid Tumor

HYPERTENSIVE EMERGENCY DUE TO RESISTANT HYPERTENSION REQUIRING SEVEN MEDICATIONS (CHEST 2025) - "The patient was eventually weaned off labetalol infusion and transitioned to oral medications which were up-titrated to maximum doses of carvedilol, chlorthalidone, clonidine, nifedipine, spironolactone, hydralazine and valsartan before nicardipine infusion was weaned off improving systolic BP (SBP) to 130s mmHg before discharge. HE should be treated immediately with intravenous antihypertensives to avoid further end-organ damage."

Addiction (Opioid and Alcohol) • Cardiovascular • Cerebral Hemorrhage • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Endocrine Disorders • Heart Failure • Hematological Disorders • Hypertension • Ischemic stroke • Nephrology • Nicotine Addiction • Ophthalmology • Renal Disease • Respiratory Diseases • Subarachnoid Hemorrhage